Incidence and Diagnosis

Sarcoidosis is a granulomatous disease that affects predominantly the lungs of young adults aged 25–45 years and to a lesser extent other organs, including the heart. The annual incidence of sarcoidosis in the United States has been estimated to be 10.9 per 100,000 in whites and 35.5 per 100,000 in African Americans. The prevalence of CS varies significantly depending on the population studied and methodology used for detection. In a series of 40 patients with systemic sarcoidosis, 17 out of 31 asymptomatic patients (54.8%) had subclinical cardiac MRI abnormalities, while in another series from the Netherlands, only 3 of 82 (3.7%) asymptomatic patients with pulmonary sarcoidosis had CS. Therefore the screening and diagnosis of CS represent a challenge for the clinician. A definite diagnosis of CS is made through the presence of non-caseating granulomas on histological examination of myocardial tissue with no alternative cause (negative organismal stains). A myocardial biopsy is not often performed. For most cases the diagnosis of CS is “probable” using the expert consensus criteria which consist of the presence of a histological diagnosis of extracardiac sarcoidosis in addition to one or more of the following: steroid +/- immunosuppressant-responsive cardiomyopathy or heart block, unexplained reduced LVEF (<40%), unexplained sustained (spontaneous or induced) VT, Mobitz type II 2nd degree or 3rd degree heart block, or a pattern consistent with cardiac sarcoidosis on cardiac PET, cardiovascular magnetic resonance (CMR) or gallium uptake study. The three major manifestations of CS are

1. conduction abnormalities,
2. ventricular arrhythmias, and
3. heart failure, yet supraventricular arrhythmias are frequently seen in patients with CS.

The exact incidence of atrial fibrillation in CS is difficult to know, as a proportion is undetected due to lack of symptoms. Cain et al., in a recent study, examined 192 consecutive patients who underwent CMR. Atrial arrhythmias were documented more frequently than ventricular arrhythmias in patients with sarcoidosis with cardiac involvement and were 3 times more prevalent than in patients with sarcoidosis without cardiac involvement. In a series of 100 patients with confirmed CS reported by Viles-Gonzalez et al., the prevalence of supraventricular arrhythmias was 32%. Atrial fibrillation was the most common arrhythmia (18%), followed by atrial tachycardia (7%), atrial flutter (5%), and other supraventricular tachycardias (2%). In study reported by Betensky et al., of 45 patients with CS and an implantable cardioverter-defibrillator (ICD), 6 patients (13.3%) received inappropriate ICD therapies mostly representing atrial fibrillation. However, it is likely that not all episodes of atrial fibrillation led to defibrillator shocks, so the true prevalence may be higher.

Mechanism

The cause of atrial fibrillation in patients with CS is likely due to granulomatous involvement of the atrium leading to inflammation and scarring, and raised end-diastolic pressures from sarcoid involvement of the lung and left ventricle. In a landmark study...
examining the clinical and autopsy findings of 113 hearts with CS, granulomas were detected in the left ventricle in 97% and in the atria in 22% of patients with symptomatic CS. Of note, 15 out of 89 patients (17%) in this study had atrial arrhythmias. While it is plausible that granulomas in the left atrium lead to scarring and the development of atrial fibrillation, there are other factors that contribute to the development of atrial arrhythmia. Left atrial enlargement (LAE) secondary to LV dysfunction is believed to be a contributing factor. In data from our center reported by Viles-Gonzalez et al, the incidence of supraventricular arrhythmias among patients with and without LAE was 267.8 and 38.3 per 1,000 person-years, respectively (RR, 6.99; 95% CI, 3.31-14.77). Among the variables studied in a multivariate analysis, LAE was the only variable associated with atrial arrhythmias. Age, race, gender, systolic and diastolic ventricular dysfunction, presence of pulmonary sarcoidosis, right atrial enlargement, mitral valve disease, systemic and pulmonary hypertension or use of steroids/immunosuppressant were not significant. In a recent report using speckle tracking echocardiography, left and right atrial reservoir functions were significantly lower in CS patients compared to controls. This report suggests that atrial mechanical function is impaired early in patients with CS before left ventricular dysfunction is seen on conventional echocardiography. The role of inflammation in the genesis of AF in these patients has been supported by a number of case series, in which glucocorticoids significantly reduced patients’ arrhythmic burden. Data from our laboratory has suggested that pulmonary vein triggers may also play a causal role: 4 out of 5 (80%) CS patients with AF who underwent pulmonary vein isolation were free from recurrent AF at a median follow up of 18 months.

**Treatment**

As discussed above CS is thought to cause atrial arrhythmias through two primary mechanisms:

1. sarcoïd infiltration of the lungs and ventricles, leading to elevated end-diastolic pressure and atrial remodeling, and
2. direct granulomatous infiltration of the atria themselves, resulting in inflammation and fibrosis. Treatment of elevated filling pressures centers on the use of cardiac-specific drugs for the management of systolic and diastolic dysfunction, and anti-arrhythmic drugs for control of symptomatic arrhythmia. While no single anti-arrhythmic drug strategy is favored, it is recommended that class IC agents generally be avoided due to the high incidence of myocardial scar in this population. Management of myocardial sarcoïd infiltration has largely employed the use of immunosuppressive therapy, though such treatment has never been assessed in a clinical trial format. As a result, choice of immunosuppressive agent, dose and duration remains widely variable in the treatment of CS.

**Immunosuppression**

In the Delphi Study, which sought to establish an expert consensus on the diagnosis and treatment of CS, it was found that clinical management varies widely among physicians. More than three-quarters, however, agreed that immunomodulatory therapy should be instituted on the basis of ventricular dysfunction or arrhythmia, or a positive FDG-PET scan. The majority indicated that they would treat CS in the presence of conduction abnormalities or a positive MRI. Prednisone was widely the treatment of choice, though there was no particular agreement on strength or duration of therapy.

Data on the use of corticosteroids for the treatment of CS has centered predominantly on the amelioration of ventricular arrhythmia, conduction block, and LV dysfunction; its use for treatment of atrial arrhythmia is largely extrapolated from such studies. A systematic review by Sadek, et al., identified 10 retrospective studies examining the utility of steroids in CS. All studies included had involved at least three patients with at minimum three months of follow up. Of those patients presenting with CS-related conduction disease, 47% showed improvement in conduction after initiation of steroids. None of the 16 patients with conduction disorders who did not received steroids improved.

Four studies have examined the effect of steroids on LV dysfunction, noting preservation or improvement in patients with normal or mild-to-moderate LV dysfunction, respectively. Those subjects with severe LV dysfunction failed to derive any benefit, perhaps a reflection of the degree of disease progression. Data on the use of corticosteroids in ventricular arrhythmia has been similarly encouraging, though its use in both studies was confined by the concomitant administration of anti-arrhythmic drugs.

Dose and duration of corticosteroid therapy remains poorly established. Most studies have recommended initiation of prednisone at 1 mg/kg per day. However, retrospective review of CS patients managed on high dose (>30 mg/day) versus low dose (<30 mg/day) prednisone showed no difference in outcome, raising the possibility that CS flares can be effectively managed on lower doses of corticosteroids, thus mitigating the many side-effects of intensive steroid therapy. Most experts at this time favor an early period of intensive prednisone therapy (approximately 0.5 mg/kg), followed by slow titration to a minimum suppressive dose (typically 5-10 mg/day). This dose is maintained indefinitely, as there are several worrisome reports of sudden death following complete cessation of steroid therapy.

Steroid-sparing immunosuppressants, including methotrexate, hydroxychloroquine, cyclophosphamide, and azathioprine, have been employed with varying degrees of success. Though their use in pulmonary sarcoidosis has become well established, data regarding their efficacy in the treatment of CS remains scarce. They are typically employed when steroid therapy becomes limited by side effects, or as an adjunct to low-dose steroid therapy.
Catheter Ablation

Research on the role of catheter ablation in the treatment of CS has focused primarily on ventricular tachycardia, in which the majority of arrhythmia is caused by macro-reentry around areas of granulomatous scar. Studies have consistently shown reasonably high procedural non-inducibility with somewhat more measured long-term success rates.\(^{\text{32-34}}\)

While more limited, data regarding the treatment of atrial arrhythmia using catheter ablation has also shown some promise. Abnormal automaticity, triggered activity, and macro-reentry have all been described in non-AF atrial arrhythmia.\(^{\text{11,35}}\) In our group’s published experience, 9 patients with CS underwent catheter ablation—2 for paroxysmal AF, 3 for persistent AF, 1 for cavitricuspid isthmus-dependent flutter, 2 for atypical flutters, and 1 for both CTI-dependent flutter and paroxysmal AF. Mean follow up was 1.8 ± 1.9 years. In the patients with paroxysmal AF, programmed stimulation with and without isoproterenol infusion failed to identify atrial triggers. Both underwent circumferential pulmonary vein isolation (PVI), and remained free from recurrence at follow up. In the patients with persistent AF, bipolar voltage mapping revealed a small area of low voltage in the septal area in one patient and diffuse, extensive left atrial scar in another (figure). Both underwent PVI and complex fractionated atrial electrogram (CFAE) ablation. The remaining patient with persistent AF had minimal atrial scar and had PVI alone. One patient had subsequent recurrence and was started on anti-arrhythmic drug therapy with good response. Microreentrant circuits were seen originating from the septum and left atrial anterior wall in the patients with atypical flutters and were successfully ablated.\(^{\text{31}}\)

The success of PVI in those patients with AF suggests a causal role of the pulmonary veins despite the diffuse nature of CS. However, not all patients underwent electro-anatomical mapping to define the extent of left and right atrial scar; further study of atrial scar burden in these patients would help better define the nature of atrial arrhythmia in CS patients.

Anticoagulation

Patients with sarcoidosis may be at increased risk of venous thromboembolism, suggesting a hypercoagulable state.\(^{\text{36}}\) It remains unknown whether CS patients with AF are at increased risk of LA thrombosis beyond traditional risk factors. Further, the efficacy of novel oral anti-coagulants (NOACs) in CS patients with AF has not been studied. At present the use of anti-coagulation, including NOACS, for CS patients with AF is suggested on the basis of the CHA2DS2-VASC score as is done for non-valvular AF, in keeping with current guidelines.\(^{\text{4}}\)

References


